| abstract |
The invention provides protein biomarkers whose change in concentration or activity level is associated with atypical hemolytic uremic syndrome (aHUS) or with clinically significant treatment of aHUS with a complement inhibitor. Compositions and methods are also provided for studying the concentration and / or activity of one or more protein biomarkers in a biological fluid. The compositions and methods are suitable, inter alia, for assessing the risk of developing aHUS, diagnosing aHUS, determining whether an individual is experiencing the first acute manifestation of aHUS, monitoring the progression or attenuation of aHUS and / or monitoring the response to treatment with a complement inhibitor or optimizing such treatment. |